India, Oct. 9 -- Eli Lilly and Company (LLY) presented new exploratory data from its Phase 3b TOGETHER-PsO trial, providing additional insight into the biological psoriasis and obesity and the potential impact of treating both conditions simultaneously.
Psoriasis is a chronic, immune-mediated skin disease that causes inflamed, scaly patches on the skin. Many people with psoriasis also live with obesity or overweight, conditions that can worsen disease burden and treatment outcomes. In the U.S., approximately 61% of people with psoriasis have obesity or overweight with at least one weight-related comorbidity.
The TOGETHER-PsO Phase 3b trial evaluated the use of Taltz, Lilly's approved psoriasis treatment, together with Zepbound, the compan...